SCHEMBL2942759

SCHEMBL2942759

O=C(Nc1ccc(Cl)cn1)c1oc2cc(Cl)cnc2c1NC(=O)C1CCC(N2CCCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 5/20 0.46
▸ LMNA P02545 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ DEGS1 O15121 1/20 0.41
▸ RAB9A P51151 2/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942756 1.00 F10 (0.46) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2946201 0.93 F10 (0.43) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2946193 0.93 F10 (0.43) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290501 0.93 GSK3B (0.46) F10SMN1; SMN2DEGS1GSK3BDYRK1A
SCHEMBL2944531 0.93 F10 (0.43) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2944525 0.93 F10 (0.43) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2948032 0.92 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2948024 0.92 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290552 0.91 HRH3 (0.46) F10LMNATSHRSMN1; SMN2RAB9A
SCHEMBL2944863 0.91 SMN1; SMN2 (0.45) F10LMNATSHRSMN1; SMN2DEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US claimed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US claimed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP claimed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 F10 4/4885LMNA 832/4885TSHR 3368/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 F10 4/4885LMNA 1796/4885TSHR 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback